Interactions of bexarotene (LGD1069, Targretin) with the coagulation system

Cancer Chemotherapy and Pharmacology

Volumn 68, Issue 4, 2011, Pages 847-854

  Hespel, Anne ^a   Mejdoubi Charef, Najet ^c   Yous, Said ^b   Courty, José ^a   Papy Garcia, Dulce ^a   Charef, Said ^a  

^a UNIVERSITÉ PARIS EST CRÉTEIL   (France)

^b Faculté des Sciences Pharmaceutiques et Biologiques Université de Lille   (France)

^c UNIVERSITÉ PARIS SACLAY   (France)

Author keywords

Anticoagulant; Bexarotene; Cancer; Coagulation factors

Indexed keywords

ANTINEOPLASTIC AGENT; BEXAROTENE; BLOOD CLOTTING FACTOR; BLOOD CLOTTING FACTOR 10; BLOOD CLOTTING FACTOR 10A; BLOOD CLOTTING FACTOR 11; BLOOD CLOTTING FACTOR 12; BLOOD CLOTTING FACTOR 5; BLOOD CLOTTING FACTOR 7; BLOOD CLOTTING FACTOR 8; BLOOD CLOTTING FACTOR 9; DRUG VEHICLE; PROTHROMBIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTICOAGULATION; ARTICLE; ASSAY; BLEEDING; BLOOD CELL; BLOOD CLOTTING; BLOOD CLOTTING DISORDER; CANCER PATIENT; CONTROLLED STUDY; CUTANEOUS T CELL LYMPHOMA; DRUG DESIGN; DRUG EFFECT; FEMALE; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; PARTIAL THROMBOPLASTIN TIME; PRIORITY JOURNAL; PROTHROMBIN TIME; THROMBOPLASTIN TIME;

ANIMALS; ANTICARCINOGENIC AGENTS; BLOOD COAGULATION; DRUG MONITORING; FACTOR IX; FACTOR X; FEMALE; HUMANS; MICE; PARTIAL THROMBOPLASTIN TIME; PROTHROMBIN TIME; TETRAHYDRONAPHTHALENES;

EID: 80054773447     PISSN: 03445704     EISSN: 14320843     Source Type: Journal    
DOI: 10.1007/s00280-010-1553-0     Document Type: Article

References (31)

1. LT Farol KB Hymes 2004 Bexarotene: a clinical review Exp Rev Anticancer Ther 4 180 188 10.1586/14737140.4.2.180 1:CAS:528:DC%2BD2cXislyrur8%3D (Pubitemid 38477332)
2. FJ Esteva J Glaspy S Baidas L Laufman L Hutchins M Dickler D Tripathy R Cohen A DeMichele RC Yocum CK Osborne DF Hayes GN Hortobagyi E Winer GD Demetri 2003 Multicenter phase II study of oral bexarotene for patients with metastatic breast cancer J Clin Oncol 21 999 1006 12637463 10.1200/JCO.2003.05.068 1:CAS:528:DC%2BD2cXpsVGqsLg%3D (Pubitemid 46594127)
3. JR Rigas KH Dragnev 2005 Emerging role of rexinoids in non-small cell lung cancer: focus on bexarotene Oncologist 10 22 33 15632250 10.1634/theoncologist.10-1-22 1:CAS:528:DC%2BD2MXhs1CjsLk%3D (Pubitemid 40171249)
4. JV Smit ME Franssen EM de Jong J Lambert DI Roseeuw J De Weert RC Yocum VJ Stevens PC van de Kerkhof 2004 A phase II multicenter clinical trial of systemic bexarotene in psoriasis J Am Acad Dermatol 51 249 256 15280844 10.1016/j.jaad.2002.08.001
5. KT Liby SpornMB YoreMM 2007 Triterpenoids and rexinoids as multifunctional agents for the prevention and treatment of cancer Nat Rev Cancer 7 357 369 17446857 10.1038/nrc2129 1:CAS:528:DC%2BD2sXksFSiu7g%3D (Pubitemid 46652485)
6. MM Gottardis ED Bischoff MA Shirley MA Wagoner RA Heyman WW Lamph 1996 Chemoprevention of mammary carcinoma by LGD1069 (Targretin): an RXR-selective ligand Cancer Res 56 5566 5570 8971154 1:CAS:528:DyaK2sXis1ah (Pubitemid 26422151)
7. RA Lubet K Christov NP Nunez, et al. 2005 Efficacy of Targretin on methylnitrosourea-induced mammary cancers: prevention and therapy dose-response curves and effects on proliferation and apoptosis Carcinogenesis 26 441 448 15591091 10.1093/carcin/bgh338 1:CAS:528:DC%2BD2MXmsVyqtg%3D%3D (Pubitemid 40246566)
8. K Wu HT Kim JL Rodriquez, et al. 2002 Suppression of mammary tumorigenesis in transgenic mice by the RXR-selective retinoid, LGD1069 Cancer Epidemiol Biomarkers Prev 11 467 474 12010861 1:CAS:528:DC%2BD38XkslagtrY%3D (Pubitemid 34517942)
9. K Wu Y Zhang XC Xu, et al. 2002 The retinoid X receptor-selective retinoid, LGD1069, prevents the developmentof estrogen receptor-negative mammary tumors in transgenic mice Cancer Res 62 6376 6380 12438218 1:CAS:528: DC%2BD38XovFOltbk%3D (Pubitemid 35364089)
10. ED Bischoff MM Gottardis RA Heyman TE Moon WW Lamph 1998 Beyond tamoxifen: the retinoid X receptor-selective ligand LGD1069 (TARGRETIN) causes complete regression of mammary carcinoma Cancer Res 58 479 484 9458093 1:CAS:528:DyaK1cXnsFeitw%3D%3D (Pubitemid 28087410)
11. ED Bischoff RA Heyman WW Lamph 1999 Effect of the retinoid X receptor-selective ligand LGD1069 on mammary carcinoma after tamoxifen failure J Natl Cancer Inst 91 2118 2123 10601384 10.1093/jnci/91.24.2118 1:CAS:528:DC%2BD3cXlslWnsg%3D%3D (Pubitemid 30019574)
12. WC Yen RY Prudente WW Lamph 2004 Synergistic effect of a retinoid X receptor-selective ligand bexarotene (LGD1069, Targretin) and paclitaxel (Taxol) inmammary carcinoma Breast Cancer ResTreat 88 141 148 10.1007/s10549-004-1426-5 1:CAS:528:DC%2BD2cXhtVWgtbzK (Pubitemid 39575571)
13. VR Agarwal ED Bischoff WW Lamph T Hermann 2000 Induction of adipocyte-specific gene expression is correlatedwithmammary tumor regression by the retinoid X receptor-ligand LGD1069 (targretin) Cancer Res 60 6033 6038 11085524 1:CAS:528:DC%2BD3cXotV2lsL4%3D
14. NA Rizvi JL Marshall W Dahut E Ness JA Truglia G Loewen GM Gill EH Ulm R Geiser D Jaunakais MJ Hawkins 1999 A Phase I study of LGD1069 in adults with advanced cancer Clin Cancer Res 5 1658 1664 10430065 1:CAS:528: DyaK1MXltVCqsbg%3D (Pubitemid 29334442)
15. M Duvic K Hymes P Heald D Breneman AG Martin P Myskowski C Crowley RC Yocum 2001 Bexarotene is effective and safe for treatment of refractory advanced-stage cutaneous Tcell lymphoma: multinational phase II-III trial results J Clin Oncol 19 2456 2471 11331325 1:CAS:528:DC%2BD3MXjvVeluro%3D (Pubitemid 32391217)
16. FR Khuri JR Rigas RA Figlin RJ Gralla DM Shin R Munden N Fox MR Huyghe Y Kean SD Reich WK Hong 2001 Multi-institutional phase I/II trial of oral bexarotene in combination with cisplatin and vinorelbine in previously untreated patients with advanced non-small-cell lung cancer J Clin Oncol 19 2626 2637 11352954 1:CAS:528:DC%2BD3MXkt1Omu74%3D (Pubitemid 32441367)
17. SR Howell MA Shirley TA Grese DA Neel KE Wells EH Ulm 2001 Bexarotene metabolism in rat, dog, and human, synthesis of oxidative metabolites, and in vitro activity at retinoid receptors Drug Metab Dispos 29 990 998 11408365 1:CAS:528:DC%2BD3MXksFCntrg%3D (Pubitemid 32605914)
18. TL Horn KE Torres JM Naylor MJ Cwik CJ Detrisac IM Kapetanovic RA Lubet JA Crowell DL McCormick 2007 Subchronic toxicity and toxicogenomic evaluation of tamoxifen citrate + bexarotene in female rats Toxicol Sci 99 612 627 17630414 10.1093/toxsci/kfm181 1:CAS:528:DC%2BD2sXhtFKru73J (Pubitemid 351753075)
19. Y Tamada M Murata T Hayashi K Goto 2002 Anticoagulant mechanism of sulfonated polyisoprenes Biomaterials 5 1375 1382 10.1016/S0142-9612(01)00258-7 (Pubitemid 34112436)
20. S Charef E Petit D Barritault J Courty JP Caruelle 2007 Effects on coagulation of a synthetic heparan mimetic given intraperitoneally or orally J Biomed Mater Res A. 83 1024 1031 17584894 (Pubitemid 350231762)
21. SH Kung JN Hagstrom D Cass SJ Tai HF Lin DW Stafford KA High 1998 Human factor IX corrects the bleeding diathesis of mice with hemophilia B Blood 3 784 790 (Pubitemid 28078279)
22. Lozier JN, Kessler CM (2005) Clinical aspects and therapy of hemophilia. In: Hoffman R, Benz E, Shattil S et al. (eds) Hematology: basic principles and practice, vol 4. Churchill Livingstone: New York, p. 2047
23. N Mackman 2004 Role of tissue factor in hemostasis, thrombosis, and vascular development Arterioscler Thromb Vasc Biol 24 1015 1022 15117736 10.1161/01.ATV.0000130465.23430.74 1:CAS:528:DC%2BD2cXkt1Ogtrk%3D (Pubitemid 38737825)
24. DM Monroe NS Key 2007 The tissue factor-factor VIIa complex: procoagulant activity, regulation, and multitasking J Thromb Haemost 5 1097 1105 17567444 10.1111/j.1538-7836.2007.02435.x 1:CAS:528:DC%2BD2sXntl2ksL0%3D (Pubitemid 46902106)
25. EW Davie JD Kulman 2006 An overview of the structure and function of thrombin Semin Thromb Hemost Suppl 1 3 15 10.1055/s-2006-939550
26. Furie B, Furie BC (2005) Molecular basis of blood coagulation. In: Hoffman R, Benz E, Shattil S et al (eds) Hematology: basic principles and practice, vol. 4. Churchill Livingstone, New York, p. 1931
27. G Lu GJ Broze Jr S Krishnaswamy 2004 Formation of factors IXa and Xa by the extrinsic pathway: differential regulation by tissue factor pathway inhibitor and antithrombin III J Biol Chem 279 17241 17249 14963035 10.1074/jbc.M312827200 1:CAS:528:DC%2BD2cXjt1Ggu7c%3D (Pubitemid 38560482)
28. N Mackman 2005 Tissue-specific hemostasis in mice Arterioscler Thromb Vasc Biol 25 2273 2281 16123318 10.1161/01.ATV.0000183884.06371.52 1:CAS:528:DC%2BD2MXhtFCisbbN (Pubitemid 41552642)
29. S Charef J Tapon-Bretaudière AM Fischer F Pflüger M Jozefowicz D Labarre 1996 Heparin-like functionalized polymer surfaces: discrimination between catalytic and adsorption processes during the course of thrombin inhibition Biomaterials 17 903 912 8718936 10.1016/0142-9612(96)83286-8 1:CAS:528:DyaK28XjtVKgt7Y%3D (Pubitemid 26136570)
30. S Charef M Jozefowicz D Labarre J Tapon-Bretaudiere AM Fischer A Bros 1990 Plasmatic antiproteinase activity enhancement by insoluble functionalized polystyrene surfaces Biomaterials 11 425 429 2207233 10.1016/0142-9612(90)90099- C 1:CAS:528:DyaK3cXmtlOkurg%3D (Pubitemid 20300838)
31. C Douzon FM Kanmangne H Serne D Labarre M Jozefowicz 1987 Heparin-like activity of insoluble sulphonated polystyrene resins. Part III: Binding of dicarboxylic amino acids Biomaterials 8 190 194 3607151 10.1016/0142-9612(87) 90062-7 1:CAS:528:DyaL2sXlsVWjtrk%3D (Pubitemid 17087379)